Answers are grounded in this paper and cite their sources.
Background The MiniMed 780G insulin delivery system has demonstrated improved hemoglobin A 1c (HbA 1c ), time in range, and quality of life (QoL) in clinical trials, but real-world studies are lacking in Southeast Asia. Objective Our study aimed to explore the preliminary efficacy and safety of the Medtronic MiniMed 780G advanced hybrid closed-loop system, as well as the impact on QoL, in Southeast Asian adults with type 1 diabetes (T1D) who were previously on either multiple daily injections or conventional pump therapy over 24 weeks. Methods A prospective, single-center pilot study was conducted in patients with T1D on multiple daily injections or conventional pump therapy. Primary end points included the change in HbA 1c at 12 and 24 weeks. Secondary end points included continuous glucose monitoring glycemic metrics, change in total daily insulin dose, QoL scores, and adverse events. Results Nine patients (n=5 male) with a mean age of 35 (SD 10.9) years completed the study. Mean HbA 1c improved from 7.3% (SD 0.9%; mean 56.3, SD 9.8 mmol/mol) to 6.9% (SD 0.6%; mean 51.2, SD 6.4 mmol/mol) at 12 weeks and 7.0% (SD 0.6%; mean 53.0, SD 6.1 mmol/mol) at 24 weeks, respectively. All patients achieved the target time in the target range of over 70%, time above the target range of less than 25%, and time below the target range of less than 4% at 12 and 24 weeks. Reduction in total daily dose of insulin was observed for all patients at 24 weeks. Conclusions Our study demonstrated the usability, safety, and possible improvement in glycemic outcomes with the MiniMed 780G system in Asian adults with T1D, independent of their baseline insulin therapies.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: